12:00 AM
 | 
Oct 18, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IL-4 Fusion Toxin: Phase II

Preliminary MRI data from 22 treated patients in NBIX's Phase II trial showed that the compound produced changes suggestive of tumor necrosis (cell death). NBIX said that the compound...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >